Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HANYANG-PICK: Single-dose Evolocumab Post-PCI
NCT07084259Phase 4Not yet recruiting
- Sponsor
- Hanyang University
- Start
- Jul 2025
- Primary completion
- Jun 2030
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 4 trial of evolocumab in coronary artery disease (CAD), sponsored by Hanyang University. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
evolocumab
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT07084259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07084259.